knulp
2 years ago
CEO wrote to me several times, I exposed to him a lot of strategies for Better return for commons, He replied no one ruled out, including sale of assets, cash distribution, special dividend, buyback, reverse merger.
Every option imo Means a sure double versus current market prices
urge2surge
2 years ago
Read them and got on stock twits. The way I see this at this point, either they've gotten interests and can close a deal or they can't. They've had since April to affect such. LOGC clearly demonstrates sector consolidation and interests. Management needs to articulate and or act. Hopefully we'll see follow through on Monday. If not, I don't see this managerial team capable of anything other than selling shares, r s, and business as usual. The P2 trial results are also over due. So maybe they'll announce this week.
Otherwise, there's no need for further speculations or discourse here imo. Speculating needs to give place to execution. Plain and simple.
Gltu
urge2surge
2 years ago
Latest take. After several emails and calls, I've gotten zero response on either. Since April's announcement on exploring options, latent P2 trial results expected first quarter, and continual depreciating market cap despite 54 million in cash and tangibles, we're either near a major reversal or the end of the end. With the Gene therapy sector gaining interests and consolidation, LOGC of latest in consolidation, we will either a see a conclusion or capitulation.
Last post here..
urge2surge
2 years ago
We have LOGC bought out at 2.07 from a base of .32 and subsequent mc of sub 70 million. They had 33 million in cash tangibles and nowhere near the developments here or patents etc. There's a suit on LOGC for selling undervalued. That'll be interesting to see what develops there.
On a comparable comparison, minimum based on doubling tangibles cash, were at 110 million. $1.50 buyout. But as I wrote, given the patents, trials, nols, should be 3-6??
urge2surge
2 years ago
Over 60 million in cash and equivalents, zero debt, in play for take over, factoring in patent portfolio, Nols, chart technicals, we're looking for a tripple at minimum from here.. Buy out IMO is north of $2.
stocktrademan
2 years ago
SIOX buy 0.430600
nice exhaustion gap and now reversal buy
find the massive macd bullish divergence on the daily and weekly charts
it just broke above the downtrend line as a buy trigger for the setup
up we go
https://siogtx.com/
https://finance.yahoo.com/quote/SIOX/profile?p=SIOX
https://www.barchart.com/stocks/quotes/SIOX
https://finviz.com/quote.ashx?t=SIOX
https://www.stockconsultant.com/consultnow/basicplus.cgi?symbol=SIOX
https://stockcharts.com/c-sc/sc?chart=SIOX,uu[e,a]dhclyiay[uu][pb5!b10!b50!b100!b200!d20,2!h.02,.20!f][vb5!b20][iut!lv8!lk9!LE12,26,9!ll14!la6,13,5!la8,17,9!la12,26,9!uc14!ub14!ub6!lo!lp7,3!lh9,3!LI14,3!lxa!ld8!lq!lg14!lf14][j20444984,y]&r=3555b
https://www.barchart.com/etfs-funds/quotes/SIOX/technical-chart?plot=CANDLE&volume=toSIOX&data=DO&density=X&pricesOn=1&asPctChange=0&logscale=1&indicators=TREND&sym=SIOX&grid=1&height=500&studyheight=100&timeframe=2%20Months
normal chart
log chart
normal chart
log chart
georgejjl
3 years ago
GREAT news this morning 3 batches at date I say 200 liter batch size.
That is EXCELLENT NEWS. That should be enough material to treat 10s of thousands if not hundreds of thousands of men and women with Parkinsonโsโ disease.
Ready for commercialization.
โTodayโs announcement is the culmination of several months of effort by the Sio and Oxford BioMedica teams focused on the development of a reliable, suspension-based manufacturing process to enable scale-up of production and advancement of the AXO-Lenti-PD program,โ said Pavan Cheruvu, M.D., Chief Executive Officer of Sio Gene Therapies. โWith the successful manufacture of three batches, all of which achieved the target titer and have completed fill and finish, we now have a process that has generated sufficient clinical trial material for future clinical development. We believe these data, coupled with scientific advice from the MHRA, help clarify the path forward and collectively represent an inflection point for the AXO-Lenti-PD program.โ
https://finance.yahoo.com/news/sio-gene-therapies-announces-successful-120000897.html
Good luck and GOD bless,
georgejjl
3 years ago
Why haven't we seen the presentation and poster regarding the following:
Presentation Title: Bicistronic AAV Gene Therapy for Tay-Sachs and Sandhoff Diseases in a Sheep Model
Presentation Number: OR30
Session: Session 4a: CNS & Sensory II
Presenting Author: Toloo Taghian, Ph.D., University of Massachusetts
Presentation Date and Time: Thursday, October 21, 2021; 9:00-11:00 AM CEST
Poster Presentation Details:
Presentation Title: Phase 1/2 Open-label Dose Evaluation Study of AXO-Lenti-PD Gene Therapy for Parkinsonโs Disease: Efficacy, Safety, and Tolerability Data up to 24 Months
Poster Number: P254
Presenting Author: Gavin Corcoran, MD, Chief R&D Officer of Sio Gene Therapies
Good luck and GOD bless,